News
The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first ...
Omada Health is poised to generate over 35% growth while approaching adjusted EBITDA breakeven, Needham analysts say.
Hinge Health and Omada Health reawakened the digital health IPO market. But most late-stage healthcare startups aren't ready ...
Shares of Omada Health finished their trading debut on the Nasdaq above their IPO price after the virtual chronic care firm priced its initial public offering in the middle of its expected range.
Newly public Omada Health says it won't turn patient care over to AI as the tech consumes investor interest.
Omada Health, a virtual chronic care provider, priced its IPO at $19 per share, at the midpoint of its $18 to $20 per share price range. The company said in a press release Thursday it sold 7.9 ...
20d
Dealbreaker on MSNOmada & Hinge’s IPO Debuts Signal Success for Digital Health Market, Experts SayMany healthcare experts are calling Omada Health and Hinge Health's IPO debuts a success, though it's still early days.
Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.
The company is not yet profitable. In 2023, Omada reported a net loss of $67.5 million, and that shrank to $47 million in 2024. The company reported a net loss of $9.4 million in the first quarter ...
Dive Brief: Omada Health went public Friday, marking the second recent digital health IPO after a dry spell for the sector.; The digital chronic condition management company opened at $23 per ...
Omada Health has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion.The company follows a successful ...
Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results